Lundbeckfonden Ventures nyheder

Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 58 59 60

Lundbeckfonden Ventures


Acacia Pharma Group PLC – PDMR Dealing/Issue of Equity
1. oktober 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
30. september 2019
Acacia Pharma Group PLC – Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
26. september 2019